Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Exclusive Content A Fresh IPO That Long-Term Investors Shouldn't IgnoreWritten by Jordan Chussler. Originally Published: 1/14/2026. 
Article Highlights - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is always a good time to revisit an initial public offering (IPO) calendar. Almost every week, companies go public, and a handful of them can offer considerable short-term upside potential. Of course, they also carry substantial downside risk. But even conservative investors who err on the side of caution should not automatically dismiss recent IPOs — some may warrant a place in long-term buy-and-hold portfolios. Gold Above $5,000 per Ounce in 2026! Here's How to Play It...
With so many strange events happening across the economy (consumer confidence plummeting, credit-card delinquencies soaring, and more), it's no wonder the richest investors are loading up on gold. But what you might not realize is that there's a much better way to profit from rising gold prices - WITHOUT ever touching an ETF, mining stock, or even bullion. Get the full details here. One biotechnology company in the healthcare sector that just went public could be an example of that. Last Year’s IPO Success Stories Last year is a strong reminder why these companies shouldn’t be dismissed by investors with lower risk tolerances. AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since then. Short-term speculators may have captured its roughly 359% gain before it reached 30 days on the Nasdaq, but longer-term holders are still enjoying strong returns. Others, such as Medline (NASDAQ: MDLN), refute the idea that IPOs are only for high-risk startups. The medical products and services provider, which debuted publicly in December 2025, was founded in 1966 and already has a market cap in excess of $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD)—famous for its ubiquitous packages of bacon—waited 89 years before its IPO. Since going public in January 2025, the stock is up nearly 5% and has rewarded shareholders with a dividend that currently yields 4.44% (about $1 per share annually), making it an immediate consideration for income investors. After its IPO, with shares beginning trading on Jan. 9, Aktis Oncology (NASDAQ: AKTS), a maker of radiopharmaceuticals, is hoping for a similar outcome in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology specializes in radiopharmaceuticals—a subset of nuclear medicine that uses radioactive drugs for both diagnostics and treatment of conditions including cancer, heart disease and neurological disorders. Specifically, radiopharmaceuticals combine radioactive isotopes with a targeting molecule that seeks out particular cells (for example, cancer cells) to deliver localized doses of radiation, minimizing damage to healthy tissue compared with conventional radiation therapy. According to industry consultancy Grand View Research, the global nuclear medicine market was estimated at nearly $18 billion in 2024 and is forecast to reach nearly $35 billion by 2030, a compound annual growth rate of about 10.16%. Importantly for Boston-based Aktis Oncology, Grand View Research says North America accounts for nearly 43% of the global nuclear medicine market, with the United States the predominant player. Aktis Oncology’s Clinical-Stage Biotechnology Wall Street expects biotech IPOs to rebound in 2026 after funding cuts in 2025 notably slowed healthcare listings. Aktis Oncology, which debuted on the Nasdaq on Jan. 9, marked the first biotech IPO of 2026 and produced one of the larger raises for a biotech in recent memory. The company raised $318 million in its IPO and now has a market cap of about $3.34 billion. According to the company’s prospectus, its executive team includes experts in drug development, approval and commercialization; members of management have helped bring 14 products to FDA approval. At a technical level, Aktis develops targeted alpha radiopharmaceuticals: a newer class of precision cancer drugs that use proprietary technology to target solid tumors while sparing healthy tissue. Aktis Oncology’s Eli Lilly Connection Notably, the firm is a clinical-stage, pre-revenue company. But that did not prevent it from attracting the attention of Eli Lilly (NYSE: LLY), which served as an anchor investor in the IPO. According to Reuters, Eli Lilly purchased $100 million worth of AKTS shares as part of the offering. That investment builds on an existing 2024 partnership between the two companies to develop tumor-targeting radiopharmaceuticals. As part of that earlier deal, Eli Lilly committed $60 million in cash alongside an equity investment in Aktis, with potential milestone payments that could exceed $1 billion. At about $1.01 trillion in market capitalization, Eli Lilly is the largest Big Pharma company by market cap; its net income rose nearly 109% year-over-year from 2023 to 2024. That momentum could continue when Eli Lilly reports Q4 and full-year 2025 financial results on Feb. 5. With its equity stake and the $100 million in AKTS shares it purchased at the IPO, the maker of Zepbound now has a sizable financial interest in Aktis’ success.
| 
